Kyverna to present interim data from Phase 2 portion of KYSA-6 study at AANEM

Kyverna Therapeutics (KYTX) announced that interim data from the Phase 2 portion of the KYSA-6 study of KYV-101 in myasthenia gravis will be presented during an oral presentation at the American Association of Neuromuscular and Electrodiagnostic Medicine, or AANEM, Annual Meeting, taking place October 29 – November 1. Following alignment with the FDA, the KYSA-6 Phase 2 open-label, single-arm, multicenter study of KYV-101 in generalized myasthenia gravis was amended into a registrational Phase 2/3 study. The interim Phase 2 results that will be presented at AANEM will include top-line efficacy and safety data for six patients with up to nine months of follow-up. At the time the abstract was submitted, five patients had been dosed; the oral presentation will report on these patients as well as early data for a sixth patient who was dosed recently. “We look forward to sharing interim data from our Phase 2 trial in myasthenia gravis, where we aim to continue to build a body of scientific evidence supporting KYV-101’s potential to deliver durable drug-free, disease-free remission with a single dose. This data readout marks an important milestone for the Company as we advance our neuroimmunology CAR T franchise – actively preparing for the initiation of the registrational Phase 3 portion of our myasthenia gravis trial this year, as well as the topline pivotal data readout for stiff person syndrome in the first half of next year,” said Warner Biddle, Chief Executive Officer of Kyverna Therapeutics.